DOCSLIB.ORG

Folotyn, INN-Pralatrexate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Folotyn, INN-Pralatrexate 19 April 2012 EMA/453346/2012 Committee for Medicinal Products for Human Use (CHMP) Final CHMP assessment report Folotyn International non-proprietary name: pralatrexate Procedure No. EMEA/H/C/002096 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 8 1.1. Submission of the dossier.................................................................................... 8 Information on Paediatric requirements ....................................................................... 8 Information relating to orphan market exclusivity.......................................................... 8 Applicant’s requests for consideration .......................................................................... 8 Conditional Marketing Authorisation ............................................................................ 8 New active Substance status ...................................................................................... 9 Protocol Assistance ................................................................................................... 9 Licensing status ..................................................................................................... 10 1.2. Steps taken for the assessment of the product ..................................................... 10 1.3. Steps taken for the re-examination procedure ...................................................... 11 2. Scientific discussion .............................................................................. 11 2.1. Introduction .................................................................................................... 11 Problem statement ................................................................................................. 11 About the product................................................................................................... 12 2.2. Quality aspects ................................................................................................ 12 2.2.1. Introduction ................................................................................................. 12 2.2.2. Active Substance........................................................................................... 12 Manufacture .......................................................................................................... 13 Specification .......................................................................................................... 13 Stability ................................................................................................................ 14 2.2.3. Finished Medicinal Product .............................................................................. 14 Pharmaceutical Development ................................................................................... 14 Adventitious agents ................................................................................................ 15 Manufacture of the product ...................................................................................... 15 Product specification ............................................................................................... 15 Stability of the product............................................................................................ 15 2.2.4. Discussion on chemical, pharmaceutical and biological aspects............................. 16 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ..................... 16 2.2.6. Recommendation(s) for future quality development............................................ 16 2.3. Non-clinical aspects .......................................................................................... 16 2.3.1. Pharmacology ............................................................................................... 16 Primary pharmacodynamic studies ............................................................................ 16 Secondary pharmacodynamic studies ........................................................................ 19 Safety pharmacology programme ............................................................................. 19 Pharmacodynamic drug interactions .......................................................................... 20 2.3.2. Pharmacokinetics .......................................................................................... 20 Methods of analysis ................................................................................................ 20 Absorption............................................................................................................. 20 Distribution............................................................................................................ 21 Metabolism ............................................................................................................ 21 Excretion............................................................................................................... 21 Pharmacokinetic drug interactions............................................................................. 22 Folotyn CHMP assessment report Page 2/85 Rev10.11 Other pharmacokinetic studies ................................................................................. 22 2.3.3. Toxicology.................................................................................................... 22 Single dose toxicity................................................................................................. 22 Repeat dose toxicity................................................................................................ 22 Genotoxicity .......................................................................................................... 25 Carcinogenicity....................................................................................................... 25 Reproduction Toxicity.............................................................................................. 26 Fertility and early embryonic development ................................................................. 26 Embryo-foetal development ..................................................................................... 26 Prenatal and postnatal development, including maternal function .................................. 26 Studies in which the offspring (juvenile animals) are dosed and/or further evaluated........ 26 Toxicokinetic data................................................................................................... 26 Local Tolerance ...................................................................................................... 27 Other toxicity studies .............................................................................................. 27 Immunotoxicity ...................................................................................................... 27 Studies on impurities .............................................................................................. 27 2.3.4. Ecotoxicity/environmental risk assessment........................................................ 28 2.3.5. Discussion on non-clinical aspects.................................................................... 28 2.3.6. Conclusion on non-clinical aspects ................................................................... 32 2.4. Clinical aspects ................................................................................................ 33 2.4.1. Introduction ................................................................................................. 33 GCP...................................................................................................................... 33 2.4.2. Pharmacokinetics .......................................................................................... 34 Absorption............................................................................................................. 34 Distribution............................................................................................................ 34 Elimination ............................................................................................................ 34 Dose proportionality and time dependencies............................................................... 35 Special populations ................................................................................................. 36 Pharmacokinetic interaction studies........................................................................... 37 Pharmacokinetics using human biomaterials ............................................................... 38 2.4.3. Pharmacodynamics........................................................................................ 38 Mechanism of action ............................................................................................... 38 Primary and Secondary pharmacology ....................................................................... 38 2.4.4. Discussion on clinical pharmacology ................................................................. 39 2.4.5. Conclusions on clinical pharmacology ..............................................................
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Clinical Policy: Pralatrexate (Folotyn)
    Clinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: 02.01.17 Last Review Date: 11.19 Coding Implications Line of Business: HIM*, Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Pralatrexate injection (Folotyn®) is a folate analog metabolic inhibitor. ____________ *For Health Insurance Marketplace (HIM), if request is through pharmacy benefit, Folotyn (40 mg/2mL vial) is non-formulary and cannot be approved using these criteria; refer to the formulary exception policy, HIM.PA.103. FDA Approved Indication(s) Folotyn is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Folotyn is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Peripheral T-Cell Lymphoma (must meet all): 1. Diagnosis of PTCL; 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Failed prior therapy (see Appendix B for examples); *Prior authorization may be required for prior therapies 5. Request meets one of the following (a or b):* a. Dose does not exceed 30 mg/m2 once weekly for 6 weeks in 7-week cycles; b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). *Prescribed regimen must be FDA-approved or recommended by NCCN.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Distinct Mechanistic Activity Prowle of Pralatrexate in Comparison to Other Antifolates in in Vitro and in Vivo Models of Human Cancers
    Cancer Chemother Pharmacol (2009) 64:993–999 DOI 10.1007/s00280-009-0954-4 ORIGINAL ARTICLE Distinct mechanistic activity proWle of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers E. Izbicka · A. Diaz · R. Streeper · M. Wick · D. Campos · R. SteVen · M. Saunders Received: 22 July 2008 / Accepted: 26 December 2008 / Published online: 17 February 2009 © The Author(s) 2009. This article is published with open access at Springerlink.com Abstract both NSCLC models, with more eVective dose-dependent Purpose This study evaluated mechanistic diVerences of TGI in the more rapidly growing NCI-H460 xenografts. pralatrexate, methotrexate, and pemetrexed. Conclusions Pralatrexate demonstrated a distinct mecha- Methods Inhibition of dihydrofolate reductase (DHFR) nistic and anti-tumor activity proWle relative to methotrex- was quantiWed using recombinant human DHFR. Cellular ate and pemetrexed. Pralatrexate exhibited enhanced uptake and folylpolyglutamate synthetase (FPGS) activity cellular uptake and increased polyglutamylation, which were determined using radiolabeled pralatrexate, metho- correlated with increased TGI in NSCLC xenograft models. trexate, and pemetrexed in NCI-H460 non-small cell lung cancer (NSCLC) cells. The tumor growth inhibition (TGI) Keywords Pralatrexate · Antifolates · Polyglutamylation · was assessed using MV522 and NCI-H460 human NSCLC Non-small cell lung cancer · Xenograft · xenografts. Dihydrofolate reductase (DHFR) Results Apparent Ki values for DHFR inhibition were 45, 26, and >200 nM for pralatrexate, methotrexate, and pemetrexed, respectively. A signiWcantly greater percent- Introduction age of radiolabeled pralatrexate entered the cells and was polyglutamylatated relative to methotrexate or pemetrexed. Folate plays a key role in the one-carbon metabolic pro- In vivo, pralatrexate showed superior anti-tumor activity in cesses essential for deoxyribonucleic acid (DNA) replica- tion.
    [Show full text]
  • Standard Oncology Criteria C16154-A
    Prior Authorization Criteria Standard Oncology Criteria Policy Number: C16154-A CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE LAST REVIEWED DATE NEXT REVIEW DATE DUE BEFORE 03/2016 12/2/2020 1/26/2022 HCPCS CODING TYPE OF CRITERIA LAST P&T APPROVAL/VERSION N/A RxPA Q1 2021 20210127C16154-A PRODUCTS AFFECTED: See dosage forms DRUG CLASS: Antineoplastic ROUTE OF ADMINISTRATION: Variable per drug PLACE OF SERVICE: Retail Pharmacy, Specialty Pharmacy, Buy and Bill- please refer to specialty pharmacy list by drug AVAILABLE DOSAGE FORMS: Abraxane (paclitaxel protein-bound) Cabometyx (cabozantinib) Erwinaze (asparaginase) Actimmune (interferon gamma-1b) Calquence (acalbrutinib) Erwinia (chrysantemi) Adriamycin (doxorubicin) Campath (alemtuzumab) Ethyol (amifostine) Adrucil (fluorouracil) Camptosar (irinotecan) Etopophos (etoposide phosphate) Afinitor (everolimus) Caprelsa (vandetanib) Evomela (melphalan) Alecensa (alectinib) Casodex (bicalutamide) Fareston (toremifene) Alimta (pemetrexed disodium) Cerubidine (danorubicin) Farydak (panbinostat) Aliqopa (copanlisib) Clolar (clofarabine) Faslodex (fulvestrant) Alkeran (melphalan) Cometriq (cabozantinib) Femara (letrozole) Alunbrig (brigatinib) Copiktra (duvelisib) Firmagon (degarelix) Arimidex (anastrozole) Cosmegen (dactinomycin) Floxuridine Aromasin (exemestane) Cotellic (cobimetinib) Fludara (fludarbine) Arranon (nelarabine) Cyramza (ramucirumab) Folotyn (pralatrexate) Arzerra (ofatumumab) Cytosar-U (cytarabine) Fusilev (levoleucovorin) Asparlas (calaspargase pegol-mknl Cytoxan (cyclophosphamide)
    [Show full text]
  • Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V
    Published OnlineFirst January 4, 2018; DOI: 10.1158/1078-0432.CCR-17-2168 Cancer Therapy: Preclinical Clinical Cancer Research Establishing a Preclinical Multidisciplinary Board for Brain Tumors Birgit V. Nimmervoll1, Nidal Boulos2, Brandon Bianski3, Jason Dapper4, Michael DeCuypere5, Anang Shelat6, Sabrina Terranova1, Hope E. Terhune4, Amar Gajjar7, Yogesh T. Patel8, Burgess B. Freeman9, Arzu Onar-Thomas10, Clinton F. Stewart11, Martine F. Roussel12, R. Kipling Guy6,13, Thomas E. Merchant3, Christopher Calabrese14, Karen D. Wright15, and Richard J. Gilbertson1 Abstract Purpose: Curing all children with brain tumors will require an Results: Mouse models displayed distinct patterns of response understanding of how each subtype responds to conventional to surgery, irradiation, and chemotherapy that varied with tumor treatments and how best to combine existing and novel therapies. subtype. Repurposing screens identified 3-hour infusions of It is extremely challenging to acquire this knowledge in the clinic gemcitabine as a relatively nontoxic and efficacious treatment of alone, especially among patients with rare tumors. Therefore, we SEP and CPC. Combination neurosurgery, fractionated irradia- developed a preclinical brain tumor platform to test combina- tion, and gemcitabine proved significantly more effective than tions of conventional and novel therapies in a manner that closely surgery and irradiation alone, curing one half of all animals with recapitulates clinic trials. aggressive forms of SEP. Experimental Design: A multidisciplinary team was established Conclusions: We report a comprehensive preclinical trial to design and conduct neurosurgical, fractionated radiotherapy platform to assess the therapeutic activity of conventional and chemotherapy studies, alone or in combination, in accurate and novel treatments among rare brain tumor subtypes.
    [Show full text]
  • Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
    Cancer drug costs for a month of treatment at initial Food and Drug Administration approval Year of FDA Monthly Cost Monthly cost Generic name Brand name(s) approval (actual $'s) (2014 $'s) vinblastine Velban 1965 $78 $586 thioguanine, 6-TG Thioguanine Tabloid 1966 $17 $124 hydroxyurea Hydrea 1967 $14 $99 cytarabine Cytosar-U, Tarabine PFS 1969 $13 $84 procarbazine Matulane 1969 $2 $13 testolactone Teslac 1969 $179 $1,158 mitotane Lysodren 1970 $134 $816 plicamycin Mithracin 1970 $50 $305 mitomycin C Mutamycin 1974 $5 $23 dacarbazine DTIC-Dome 1975 $29 $128 lomustine CeeNU 1976 $10 $42 carmustine BiCNU, BCNU 1977 $33 $129 tamoxifen citrate Nolvadex 1977 $44 $170 cisplatin Platinol 1978 $125 $454 estramustine Emcyt 1981 $420 $1,094 streptozocin Zanosar 1982 $61 $150 etoposide, VP-16 Vepesid 1983 $181 $430 interferon alfa 2a Roferon A 1986 $742 $1,603 daunorubicin, daunomycin Cerubidine 1987 $533 $1,111 doxorubicin Adriamycin 1987 $521 $1,086 mitoxantrone Novantrone 1987 $477 $994 ifosfamide IFEX 1988 $1,667 $3,336 flutamide Eulexin 1989 $213 $406 altretamine Hexalen 1990 $341 $618 idarubicin Idamycin 1990 $227 $411 levamisole Ergamisol 1990 $105 $191 carboplatin Paraplatin 1991 $860 $1,495 fludarabine phosphate Fludara 1991 $662 $1,151 pamidronate Aredia 1991 $507 $881 pentostatin Nipent 1991 $1,767 $3,071 aldesleukin Proleukin 1992 $13,503 $22,784 melphalan Alkeran 1992 $35 $59 cladribine Leustatin, 2-CdA 1993 $764 $1,252 asparaginase Elspar 1994 $694 $1,109 paclitaxel Taxol 1994 $2,614 $4,176 pegaspargase Oncaspar 1994 $3,006 $4,802
    [Show full text]
  • Chemotherapeutic Drugs in Lebanese Surface Waters: Estimation of Population Exposure and Identifcation of High-Risk Drugs
    Chemotherapeutic Drugs in Lebanese Surface Waters: Estimation of Population Exposure and Identication of High-Risk Drugs Yolande Saab ( [email protected] ) School of Pharmacy, Lebanese American University, Lebanon Zahi Nakad School of Engineering, Lebanese American University, Lebanon Rita Rahme School of Pharmacy, Lebanese American University, Lebanon Research Keywords: Anticancer drugs, micropollutants, risk assessment, predicted environmental concentrations, WWTP, surface waters, Lebanon Posted Date: November 3rd, 2020 DOI: https://doi.org/10.21203/rs.3.rs-98879/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Environmental risk assessment of anti-cancer drugs and their transformation products is a major concern worldwide due to two main factors: the consumption of chemotherapeutic agents is increasing throughout the years and conventional water treatment processes seem to be ineffective. The aim of the study is to investigate the consumption of anticancer drugs and assess their potential health hazard as contaminants of the Lebanese surface waters. Data on yearly consumption of 259 anti-neoplastic drugs over the years 2013 to 2018 were collected and the following parameters were calculated: yearly consumption of single active ingredients, yearly consumption of drug equivalents (for drugs belonging to the same pharmacologic class/ having the same active ingredient) and Predicted Environmental Concentrations. The classication of compounds into risk categories was based on exposure using Predicted Environmental Concentrations (PECs). The top ve most commonly consumed drugs are Mycophenolate mofetil, Hydroxycarbamide, Capecitibine, Mycophenolic acid and Azathioprine. Based on the calculated PEC values of single active ingredients as well as their equivalents, six high risk priority compounds were identied: Mycophenolate mofetil, Hydroxycarbamide, Capecitibine, Mycophenolic acid and Azathioprine and 5-Fluorouracil.
    [Show full text]
  • Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan
    March 14, 2013 Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled® Melphalan ● Product candidate is being investigated as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. ● Melphalan has been granted Orphan designation by the FDA for this indication. ● In a previous Phase 2 study, Captisol-enabled melphalan had acceptable safety findings, and it met the requirements for establishment of bioequivalence to the current commercial intravenous formulation of melphalan. ● Spectrum anticipates NDA filing in the first half of 2014 with potential commercial launch the following year, subject to FDA approval. HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the Company has gained global development and commercialization rights to Ligand Pharmaceuticals' (NASDAQ: LGND) Captisol-enabled®, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization. "We are pleased to add this late-stage program to our portfolio, which includes belinostat, for which we anticipate an NDA filing mid-year, and apaziquone, for which we expect to file an NDA in 2014," stated Rajesh C.
    [Show full text]
  • Guidelines for the Management Peripheral T-Cell Lymphoma
    BCSH Guidelines for the Management of Mature T-cell and NK-cell Neoplasms: Excluding cutaneous T-cell Lymphoma Updated August 2013 Guidelines for the Management of Mature T-cell and NK-cell Neoplasms (Excluding cutaneous T-cell Lymphoma) Updated August 2013 British Committee for Standards in Haematology Address for Correspondence: BCSH Secretary British Society for Haematology 100 White Lion Street London N1 9PF e-mail: [email protected] Writing Group: C Dearden1, R Johnson2, R Pettengell3, S Devereux4, K Cwynarski5, S Whittaker6 and A McMillan7. Disclaimer While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society of Haematology nor the publishers accept any legal responsibility for the content of these guidelines 1 The Royal Marsden NHS Foundation Trust, London 2 St James Hospital, Leeds 3 St George’s Hospital, London 4 Kings College Hospital, London 5 Royal Free Hospital, London 6 St Johns Institute of Dermatology, London 7 Nottingham University Hospital NHS Trust, Nottingham Page 1 of 99 BCSH Guidelines for the Management of Mature T-cell and NK-cell Neoplasms: Excluding cutaneous T-cell Lymphoma Updated August 2013 Introduction The mature or peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. Natural killer (NK) cells are closely related to T cells and neoplasms derived from these are therefore considered within the same group. The World Health Organisation (WHO) classification of haemopoietic malignancies has divided this group of disorders into those with predominantly leukaemic (disseminated), nodal, extra-nodal or cutaneous presentation (Harris et al, 1999, Swerdlow et al, 2008) (Table 1).
    [Show full text]
  • Durable Response to Pralatrexate for Aggressive PTCL Subtypes
    Case Report Durable response to pralatrexate for aggressive PTCL subtypes Ahmed Farhan; Lauren E Strelec, BS; Stephen J Schuster, MD; Drew Torigian, MD; Mariusz Wasik, MD; Sam Sadigh, MD; Anthony R Mato, MD; Sunita Dwivedy Nasta, MD; Dale Frank, MD; and Jakub Svoboda, MD aLymphoma Program, Abrahamson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania eripheral T-cell lymphoma (PTCL) is a het- a 4-week treatment cycle for cutaneous T-cell erogeneous group of mature T- and natural lymphomas.5 killer-cell neoplasms that comprise about In this case series, we examine the outcomes of 10%-15% of all non-Hodgkin lymphomas in the 2 patients with particularly aggressive subtypes P 1,2 United States. The development of effective thera- of PTCL who were treated with pralatrexate. The pies for PTCL has been challenging because of the significance of this report is in describing the long rare nature and heterogeneity of these lymphomas. duration of response and reporting on a PTCL sub- Most therapies are a derivative of aggressive B-cell type – subcutaneous panniculitis-like T-cell lym- lymphoma therapies, including CHOP (cyclophos- phoma, alpha/beta type – that was underrepresented phamide, hydroxydaunorubicin, vinicristine, predni- in the PROPEL study and is underreported in the sone) and CHOEP (cyclophosphamide, hydroxy- literature. daunorubicin, vinicristine, etoposide, prednisone).1 Many centers use autologous or allogeneic stem Case presentations and summaries cell transplant in this setting,1 but outcomes remain Case 1 poor
    [Show full text]
  • Pralatrexate Pharmacology and Clinical Development
    Published OnlineFirst August 21, 2013; DOI: 10.1158/1078-0432.CCR-12-2251 Clinical Cancer CCR Drug Updates Research Pralatrexate Pharmacology and Clinical Development Enrica Marchi1, Michael Mangone2, Kelly Zullo1, and Owen A. O'Connor1 Abstract Folates are well known to be essential for many cellular processes, including cellular proliferation. As a consequence, antifolates, the fraudulent mimics of folic acid, have been shown to be potent therapeutic agents in many cancers. Over the past several decades, efforts to improve on this class of drugs have met with little success. Recently, one analog specifically designed to have high affinity for the reduced folate carrier, which efficiently internalizes natural folates and antifolates, has been shown to be very active in T-cell lymphoma. Pralatrexate, approved by the U.S. Food and Drug Administration in 2009, is highly active across many lymphoid malignancies, including chemotherapy-resistant T-cell lymphoma. Emerging combination studies have now shown that pralatrexate is highly synergistic with gemcitabine, histone deacetylase inhibitors like romidepsin and bortezomib. These insights are leading to a number of novel phase I and II combination studies which could challenge existing regimens like CHOP, and improve the outcome of patients with T-cell lymphoma Clin Cancer Res; 19(22); 1–5. Ó2013 AACR. Introduction pharmacology of antifolates has led to structural analogs Mammalian cells lack the ability to synthesize folates. with markedly improved activity, which includes the recent- Consequently, these hydrophilic anionic molecules must ly U.S. Food and Drug Administration (FDA)-approved be actively transported across the cellular membrane via agent, pralatrexate. sophisticated carrier-mediated transport systems, which include the reduced folate carrier (RFC), the folate recep- Pharmacology tors, and the recently discovered proton-coupled folate Pralatrexate (10-propargyl-10-deazaaminopterin) is a transporter, or the soluble carrier 46A1 (SLC46A1; ref.
    [Show full text]